Study of Pirtobrutinib (LOXO-305) in Participants With Impaired Liver Function and Healthy Participants
Status:
Completed
Trial end date:
2021-12-30
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to measure how much of pirtobrutinib (LOXO-305) gets into
the bloodstream and how long it takes the body to eliminate it in participants with impaired
liver function and healthy participants. The side effects and tolerability of pirtobrutinib
will also be evaluated. Participation could last about 46 days.